These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 30185381)

  • 21. Comparison of survival between primary debulking surgery and neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomised trial.
    Onda T; Satoh T; Ogawa G; Saito T; Kasamatsu T; Nakanishi T; Mizutani T; Takehara K; Okamoto A; Ushijima K; Kobayashi H; Kawana K; Yokota H; Takano M; Kanao H; Watanabe Y; Yamamoto K; Yaegashi N; Kamura T; Yoshikawa H;
    Eur J Cancer; 2020 May; 130():114-125. PubMed ID: 32179446
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Primary surgery or interval debulking for advanced epithelial ovarian cancer: does it matter?
    Markauskas A; Mogensen O; dePont Christensen R; Jensen PT
    Int J Gynecol Cancer; 2014 Oct; 24(8):1420-8. PubMed ID: 25180461
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Continuous improvement in primary Debulking surgery for advanced ovarian cancer: Do increased complete gross resection rates independently lead to increased progression-free and overall survival?
    Tseng JH; Cowan RA; Zhou Q; Iasonos A; Byrne M; Polcino T; Polen-De C; Gardner GJ; Sonoda Y; Zivanovic O; Abu-Rustum NR; Long Roche K; Chi DS
    Gynecol Oncol; 2018 Oct; 151(1):24-31. PubMed ID: 30126704
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recurrence patterns of advanced ovarian, fallopian tube, and peritoneal cancers after complete cytoreduction during interval debulking surgery.
    Usami T; Kato K; Taniguchi T; Abe A; Nomura H; Yamamoto A; Matoda M; Okamoto S; Kondo E; Omatsu K; Kawamata Y; Takeshima N
    Int J Gynecol Cancer; 2014 Jul; 24(6):991-6. PubMed ID: 24905612
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602.
    Onda T; Satoh T; Saito T; Kasamatsu T; Nakanishi T; Nakamura K; Wakabayashi M; Takehara K; Saito M; Ushijima K; Kobayashi H; Kawana K; Yokota H; Takano M; Takeshima N; Watanabe Y; Yaegashi N; Konishi I; Kamura T; Yoshikawa H;
    Eur J Cancer; 2016 Sep; 64():22-31. PubMed ID: 27323348
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Validation of Revised FIGO Staging Classification for Cancer of the Ovary, Fallopian Tube, and Peritoneum Based on a Single Histological Type.
    Toptas T; Pestereli E; Erol O; Bozkurt S; Erdogan G; Simsek T
    Int J Gynecol Cancer; 2016 Jul; 26(6):1012-9. PubMed ID: 27206284
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Implementation of Extensive Cytoreduction Resulted in Improved Survival Outcomes for Patients with Newly Diagnosed Advanced-Stage Ovarian, Tubal, and Peritoneal Cancers.
    Raspagliesi F; Bogani G; Ditto A; Martinelli F; Chiappa V; Borghi C; Scaffa C; Morano F; Maltese G; Lorusso D
    Ann Surg Oncol; 2017 Oct; 24(11):3396-3405. PubMed ID: 28795373
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exploring the impact of income and race on survival for women with advanced ovarian cancer undergoing primary debulking surgery at a high-volume center.
    Cowan RA; Tseng J; Ali N; Dearie H; Murthy V; Gennarelli RL; Iasonos A; Abu-Rustum NR; Chi DS; Long Roche KC; Brown CL
    Gynecol Oncol; 2018 Apr; 149(1):43-48. PubMed ID: 29605049
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efforts at maximal cytoreduction improve survival in ovarian cancer patients, even when complete gross resection is not feasible.
    Wallace S; Kumar A; Mc Gree M; Weaver A; Mariani A; Langstraat C; Dowdy S; Bakkum-Gamez J; Cliby W
    Gynecol Oncol; 2017 Apr; 145(1):21-26. PubMed ID: 28159407
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Surgical outcomes and national comprehensive cancer network compliance in advanced ovarian cancer surgery in a low volume military treatment facility.
    Phippen NT; Barnett JC; Lowery WJ; Miller CR; Leath CA
    Gynecol Oncol; 2013 Oct; 131(1):158-62. PubMed ID: 23872110
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Has time to chemotherapy from primary debulking surgery in advanced ovarian cancer an impact on survival? - A population-based nationwide SweGCG study.
    Dahm-Kähler P; Rådestad AF; Holmberg E; Borgfeldt C; Bjurberg M; Sköld C; Hellman K; Kjølhede P; Stålberg K; Åvall-Lundqvist E
    Gynecol Oncol; 2024 Jul; 186():69-76. PubMed ID: 38603954
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The impact of perioperative β blocker use on patient outcomes after primary cytoreductive surgery in high-grade epithelial ovarian carcinoma.
    Al-Niaimi A; Dickson EL; Albertin C; Karnowski J; Niemi C; Spencer R; Shahzad MM; Uppal S; Saha S; Rice L; Nally AM
    Gynecol Oncol; 2016 Dec; 143(3):521-525. PubMed ID: 27693123
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A preoperative low cancer antigen 125 level (≤25.8 mg/dl) is a useful criterion to determine the optimal timing of interval debulking surgery following neoadjuvant chemotherapy in epithelial ovarian cancer.
    Morimoto A; Nagao S; Kogiku A; Yamamoto K; Miwa M; Wakahashi S; Ichida K; Sudo T; Yamaguchi S; Fujiwara K
    Jpn J Clin Oncol; 2016 Jun; 46(6):517-21. PubMed ID: 26977055
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimal primary surgical treatment for advanced epithelial ovarian cancer.
    Elattar A; Bryant A; Winter-Roach BA; Hatem M; Naik R
    Cochrane Database Syst Rev; 2011 Aug; 2011(8):CD007565. PubMed ID: 21833960
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patterns of Recurrence and Clinical Outcome of Patients With Stage IIIC to Stage IV Epithelial Ovarian Cancer in Complete Response After Primary Debulking Surgery Plus Chemotherapy or Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery: An Italian Multicenter Retrospective Study.
    Gadducci A; Cosio S; Zizioli V; Notaro S; Tana R; Panattoni A; Sartori E
    Int J Gynecol Cancer; 2017 Jan; 27(1):28-36. PubMed ID: 27870700
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aggressive surgery could overcome the extent of initial peritoneal dissemination for advanced ovarian, fallopian tube, and peritoneal carcinoma.
    Nishikimi K; Tate S; Matsuoka A; Shozu M
    Sci Rep; 2020 Dec; 10(1):21307. PubMed ID: 33277564
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Management of advanced ovarian cancer in South West Wales - a comparison between primary debulking surgery and primary chemotherapy treatment strategies in an unselected, consecutive patient cohort.
    Drews F; Bertelli G; Lutchman-Singh K
    Cancer Epidemiol; 2017 Aug; 49():85-91. PubMed ID: 28599137
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic Factors in Patients Undergoing Primary Cytoreductive Surgery for FIGO Stage IIIC Ovarian, Tubal or Peritoneal Cancer.
    Kaban A; Topuz S; Saip P; Sözen H; Salihoğlu Y
    J Obstet Gynaecol Can; 2018 Apr; 40(4):447-453. PubMed ID: 29055648
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of residual disease on overall survival in women with Federation of Gynecology and Obstetrics stage IIIB-IIIC vs stage IV epithelial ovarian cancer after primary surgery.
    Sørensen SM; Schnack TH; Høgdall C
    Acta Obstet Gynecol Scand; 2019 Jan; 98(1):34-43. PubMed ID: 30168853
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer.
    Zivanovic O; Eisenhauer EL; Zhou Q; Iasonos A; Sabbatini P; Sonoda Y; Abu-Rustum NR; Barakat RR; Chi DS
    Gynecol Oncol; 2008 Feb; 108(2):287-92. PubMed ID: 17996927
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.